1. Cell Cycle/DNA Damage Epigenetics Apoptosis
  2. HDAC Apoptosis Caspase
  3. BG45

BG45 is a potent HDAC3 inhibitor with IC50 values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis.

For research use only. We do not sell to patients.

BG45 Chemical Structure

BG45 Chemical Structure

CAS No. : 926259-99-6

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 79 In-stock
Solution
10 mM * 1 mL in DMSO USD 79 In-stock
Solid
5 mg USD 72 In-stock
10 mg USD 120 In-stock
50 mg USD 360 In-stock
100 mg USD 576 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Top Publications Citing Use of Products

    BG45 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2018 Apr;39(4):1957-1965.  [Abstract]

    Cells are treated with 10 mM Metformin, 10 μM BG45, or the combination of both drugs for 48 h, and then lysates are collected and apoptosis-associated markers are examined via western blot analysis.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    BG45 is a potent HDAC3 inhibitor with IC50 values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis[1][2].

    IC50 & Target[2]

    HDAC3

    0.289 μM (IC50)

    HDAC1

    2.0 μM (IC50)

    HDAC2

    2.2 μM (IC50)

    HDAC6

    >20 μM (IC50)

    In Vitro

    BG45 (1.875-30 µM; 48 and 72 h) targets multiple myeloma (MM) cells and inhibits cell growth in a dose-dependent manner[1].
    BG45 (15 µM; 0-48 h; MM.1S cells) induces apoptosis via caspase-3/PARP cleavage[1].
    BG45 (10 and 20 µM; 12 h; MM.1S cells) induces acetylation of histone H2A, H3, and H4 in a dose-dependent manner[1].
    BG45 (10 and 20 µM; 10 h; MM.1S cells) induces multiple myeloma (MM) cells toxicity is associated with hyperacetylation of histones and STAT3 and downregulation of p-STAT3[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[1]

    Cell Line: MM.1S, RPMI8226, U266, OPM1, and H929 cells
    Concentration: 1.875, 3.75, 7.5, 15, and 30 µM
    Incubation Time: 48 and 72 hours
    Result: Inhibited multiple myeloma (MM) cells growth in a dose-dependent manner.

    Western Blot Analysis[1]

    Cell Line: MM.1S cells
    Concentration: 15 µM
    Incubation Time: 0, 6, 12, 24, and 48 hours
    Result: Induced caspase-dependent apoptosis in multiple myeloma (MM) cells.

    Western Blot Analysis[1]

    Cell Line: MM.1S cells
    Concentration: 10 and 20 µM
    Incubation Time: 12 hours
    Result: Increased acetylation of histone in a dose-dependent manner.

    Western Blot Analysis[1]

    Cell Line: MM.1S cells
    Concentration: 10 and 20 µM
    Incubation Time: 10 hours
    Result: Downregulated p-STAT3 in a dose-dependent manner.
    Increased acetylation of STAT3 in MM.1S cells.
    In Vivo

    BG45 (15-50 mg/kg; i.p.; 5 days a week for 3 weeks; CB17 SCID mice with MM.1S xenograft model) inhibits human multiple myeloma (MM) cells growth and enhances bortezomib (HY-10227) induced cytotoxicity in vivo[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: CB17 SCID mice (48-54 days old) with MM.1S xenograft model[1]
    Dosage: 15 and 50 mg/kg
    Administration: Intraperitoneal injection; 5 days a week for 3 weeks
    Result: Inhibited MM tumor growth in a dose-dependent fashion.
    Enhanced either single agent activity in combination with bortezomib (HY-10227).
    Molecular Weight

    214.22

    Formula

    C11H10N4O

    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C(C1=NC=CN=C1)NC2=CC=CC=C2N

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 48 mg/mL (224.07 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.6681 mL 23.3405 mL 46.6810 mL
    5 mM 0.9336 mL 4.6681 mL 9.3362 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (11.67 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (11.67 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 4.6681 mL 23.3405 mL 46.6810 mL 116.7025 mL
    5 mM 0.9336 mL 4.6681 mL 9.3362 mL 23.3405 mL
    10 mM 0.4668 mL 2.3340 mL 4.6681 mL 11.6702 mL
    15 mM 0.3112 mL 1.5560 mL 3.1121 mL 7.7802 mL
    20 mM 0.2334 mL 1.1670 mL 2.3340 mL 5.8351 mL
    25 mM 0.1867 mL 0.9336 mL 1.8672 mL 4.6681 mL
    30 mM 0.1556 mL 0.7780 mL 1.5560 mL 3.8901 mL
    40 mM 0.1167 mL 0.5835 mL 1.1670 mL 2.9176 mL
    50 mM 0.0934 mL 0.4668 mL 0.9336 mL 2.3340 mL
    60 mM 0.0778 mL 0.3890 mL 0.7780 mL 1.9450 mL
    80 mM 0.0584 mL 0.2918 mL 0.5835 mL 1.4588 mL
    100 mM 0.0467 mL 0.2334 mL 0.4668 mL 1.1670 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    BG45
    Cat. No.:
    HY-18712
    Quantity:
    MCE Japan Authorized Agent: